Advertisement
RVMD vs SYRE
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RVMD is a Hold and SYRE is a Hold.
RVMD in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 05, 2026
RVMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 33 of 36 cases where RVMD's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RVMD's RSI Indicator exited the oversold zone, 15 of 18 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 62 cases where RVMD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Moving Average Convergence Divergence (MACD) for RVMD just turned positive on October 29, 2026. Looking at past instances where RVMD's MACD turned positive, the stock continued to rise in 31 of 43 cases over the following month. The odds of a continued upward trend are 72%.
Following a +12.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where RVMD advanced for three days, in 243 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RVMD as a result. In 63 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.
RVMD moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for RVMD crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 5 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 56%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RVMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
The Aroon Indicator for RVMD entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 5 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. RVMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.813) is normal, around the industry mean (3.498). P/E Ratio (-21.678) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. RVMD's P/S Ratio (10000.000) is very high in comparison to the industry average of (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
SYRE's RSI Oscillator peaks and leaves overbought zone
The 10-day RSI Oscillator for SYRE moved out of overbought territory on November 10, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 instances where the indicator moved out of the overbought zone. In 24 of the 27 cases the stock moved lower in the days that followed. This puts the odds of a move down at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 15 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
SYRE broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on SYRE as a result. In 63 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for SYRE just turned positive on October 20, 2026. Looking at past instances where SYRE's MACD turned positive, the stock continued to rise in 39 of 41 cases over the following month. The odds of a continued upward trend are 90%.
SYRE moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SYRE crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.
Following a +12.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYRE advanced for three days, in 261 of 300 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
The Aroon Indicator entered an Uptrend today. In 148 of 174 cases where SYRE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.592) is normal, around the industry mean (3.498). P/E Ratio (-54.111) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (526.316) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SYRE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
RVMD | SYRE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 19 | 84 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 96 Overvalued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 5 | 100 | |
SMR RATING 1..100 | 98 | 96 | |
PRICE GROWTH RATING 1..100 | 36 | 34 | |
P/E GROWTH RATING 1..100 | 54 | 54 | |
SEASONALITY SCORE 1..100 | n/a | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SYRE's Valuation (4) in the Pharmaceuticals Major industry is significantly better than the same rating for RVMD (96) in the null industry. This means that SYRE’s stock grew significantly faster than RVMD’s over the last 12 months.
RVMD's Profit vs Risk Rating (5) in the null industry is significantly better than the same rating for SYRE (100) in the Pharmaceuticals Major industry. This means that RVMD’s stock grew significantly faster than SYRE’s over the last 12 months.
SYRE's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as RVMD (98) in the null industry. This means that SYRE’s stock grew similarly to RVMD’s over the last 12 months.
SYRE's Price Growth Rating (34) in the Pharmaceuticals Major industry is in the same range as RVMD (36) in the null industry. This means that SYRE’s stock grew similarly to RVMD’s over the last 12 months.
SYRE's P/E Growth Rating (54) in the Pharmaceuticals Major industry is in the same range as RVMD (54) in the null industry. This means that SYRE’s stock grew similarly to RVMD’s over the last 12 months.
| RVMD | SYRE | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 83% | 1 day ago 89% |
| Stochastic ODDS (%) | 1 day ago 87% | 1 day ago 83% |
| Momentum ODDS (%) | 1 day ago 70% | 1 day ago 81% |
| MACD ODDS (%) | 1 day ago 72% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 71% | 1 day ago 87% |
| TrendMonth ODDS (%) | 1 day ago 74% | 1 day ago 88% |
| Advances ODDS (%) | 3 days ago 80% | 3 days ago 87% |
| Declines ODDS (%) | 1 day ago 68% | 7 days ago 86% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 82% |
| Aroon ODDS (%) | 1 day ago 79% | 1 day ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RVMD’s FA Score shows that 1 FA rating(s) are green while SYRE’s FA Score has 1 green FA rating(s).
- RVMD’s FA Score: 1 green, 4 red.
- SYRE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RVMD’s TA Score shows that 6 TA indicator(s) are bullish while SYRE’s TA Score has 6 bullish TA indicator(s).
- RVMD’s TA Score: 6 bullish, 4 bearish.
- SYRE’s TA Score: 6 bullish, 4 bearish.
Price Growth
RVMD (@Biotechnology) experienced а -0.60% price change this week, while SYRE (@Biotechnology) price change was +7.86% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
RVMD is expected to report earnings on Mar 01, 2027.
SYRE is expected to report earnings on Mar 04, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
RVMD and
Correlation & Price change
A.I.dvisor indicates that over the last year, RVMD has been loosely correlated with GLUE. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if RVMD jumps, then GLUE could also see price increases.
| Ticker / NAME | Correlation To RVMD | 1D Price Change % | ||
|---|---|---|---|---|
| RVMD | 100% | -6.40% | ||
| GLUE - RVMD | 44% Loosely correlated | -1.81% | ||
| SYRE - RVMD | 40% Loosely correlated | +2.24% | ||
| ARRY - RVMD | 39% Loosely correlated | +9.94% | ||
| AXON - RVMD | 39% Loosely correlated | +4.26% | ||
| REPL - RVMD | 38% Loosely correlated | -6.44% | ||
More | ||||
SYRE and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with ORKA. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then ORKA could also see price increases.
| Ticker / NAME | Correlation To SYRE | 1D Price Change % | ||
|---|---|---|---|---|
| SYRE | 100% | +2.24% | ||
| ORKA - SYRE | 51% Loosely correlated | -2.13% | ||
| IMVT - SYRE | 46% Loosely correlated | +3.72% | ||
| PHVS - SYRE | 46% Loosely correlated | +0.56% | ||
| TSHA - SYRE | 45% Loosely correlated | +0.12% | ||
| BEAM - SYRE | 45% Loosely correlated | +2.62% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IYW | 236.70 | 5.89 | +2.55% |
| iShares U.S. Technology ETF (IYW) | |||
| VPX | 29.73 | 0.65 | +2.24% |
| Variant Perception Cycle Aware US Equity ETF (VPX) | |||
| CMDT | 30.15 | 0.34 | +1.14% |
| PIMCO Commodity Strategy Active Exchange-Traded Fund (CMDT) | |||
| FT | 7.48 | 0.04 | +0.54% |
| Franklin Universal Trust | |||
| KPDD | 4.86 | N/A | N/A |
| KraneShares 2x Long PDD Daily ETF (KPDD) | |||